Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

famitinib 1camrelizumab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Non-squamous Non-small-cell Lung Cancer × Clear all
NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
48 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT05849246 2024-08-20

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Terminated
4 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡